

Inflammation and thrombosis in diabetes

Katharina Hess; Peter J. Grant

Division of Cardiovascular and Diabetes Research, Leeds Institute of Genetics, Health and Therapeutics, University of Leeds, Leeds, UK

Summary

Patients with diabetes mellitus are at increased risk of cardiovascular morbidity and mortality. Atherothrombosis, defined as atherosclerotic lesion disruption with superimposed thrombus formation, is the most common cause of death among these patients. Following plaque rupture, adherence of platelets is followed by local activation of coagulation, the formation of a cross-linked fibrin clot and the development of an occlusive platelet rich fibrin mesh. Patients with diabetes exhibit a thrombotic risk clustering which is composed of hyper-reactive platelets, up regulation of pro-thrombotic markers and suppression of fibrinolysis. These changes are mainly mediated by the presence of insulin

resistance and dysglycaemia and an increased inflammatory state which directly affects platelet function, coagulation factors and clot structure. This prothrombotic state is related to increased cardiovascular risk and may account for the reduced response to antithrombotic therapeutic approaches, underpinning the need for adequate antithrombotic therapy in patients with diabetes to reduce their cardiovascular mortality.

Keywords

Diabetes mellitus, inflammation, thrombosis, cardiovascular disease

Correspondence to:

Prof. Peter J. Grant
Division of Cardiovascular and Diabetes Research
Leeds Institute of Genetics, Health and Therapeutics, LIGHT Laboratories
Clarendon Way, University of Leeds, Leeds LS2 9JT, UK
Tel.: +44 113 343 7721, Fax: +44 113 343 7738
E-mail: P.J.Grant@leeds.ac.uk

Received: November 18, 2010

Accepted after minor revision: February 14, 2011

Prepublished online: April 11, 2011

doi:10.1160/THS10-11-0739

Thromb Haemost 2011; 105 (Suppl 1): S43–S54

Introduction

The prevalence of diabetes mellitus is rising with studies predicting more than 350 million people affected by 2030 (1). This population is at major risk for the development of cardiovascular disease (CVD) and consequent morbidity and mortality (2). Myocardial infarction and sudden cardiac death are the clinical manifestations of atherothrombosis, which is defined as atherosclerotic plaque rupture with superimposed thrombus formation (3). Several studies demonstrated that diabetic patients without prior cardiovascular disease have the same rate of myocardial infarction (MI) compared to non-diabetic subjects who had a previous event (4–6), highlighting the high risk of this population. The majority of diabetic patients have evidence of underlying insulin resistance (7), which in type 2 patients occurs prior to clinical presentation and is characterised by a reduction in sensitivity to the action of insulin preceding the development of beta cell failure and hyperglycaemia, the latter being dominant features of longstanding diabetes. Low grade inflammation is now widely accepted to be one link between insulin resistance, type 2 diabetes and CVD (8, 9). The origins of the heightened inflammatory activity are diverse, although abdominal obesity is thought to play a central role in this process (10, 11). The present review will focus on the effects of inflammation, insulin resistance and hyperglycaemia on thrombotic risk in diabetes patients.

Role of inflammation in atherothrombosis

Arteriosclerosis is recognised as a chronic inflammatory disorder which starts at an early age. Various changes, including insulin resistance, oxidative and shear stress lead to reduced endothelial function, promoting the migration of immune cells (macrophages and T-lymphocytes) into the vascular wall (12, 13). Later in atherogenesis, proliferation of smooth muscle cells (SMCs) and deposition of collagen increases, resulting in the development of an arteriosclerotic plaque which is protected by a fibrous cap comprised of collagen, elastin and proteoglycans derived from SMCs (3). Arteriosclerotic plaque may remain asymptomatic for many decades as the disease progresses. However, in susceptible individuals, inflammatory cells within the lesion expressing matrix-degrading metalloproteinases (MMPs) and other proteases such as cathepsin and tryptase/chymase result in enhanced matrix breakdown (14). These processes lead to thinning of the fibrous cap which may give rise to plaque rupture and superimposed thrombus formation, causing the acute complications of CVD, including unstable angina (UA) and MI.

Following plaque rupture, thrombosis is initiated when thrombotic components of the plaque are exposed to circulating blood. Platelet activation at the site of injury plays a major role in thrombus formation and proceeds in three stages: i) an initiation phase involving platelet adhesion, ii) an extension phase which includes activation, additional recruitment and aggregation of platelets, and iii) a perpetuation phase composed of platelet stimulation and stabilisation of clots (15). During the initiation phase platelets roll,

adhere, and spread on the collagen matrix to form an activated platelet monolayer. Adhesion is mediated by interaction between the glycoprotein (GP) Ib/V/IX receptor complex on the platelet surface with von Willebrand factor (vWF) and between the GP VI and GP Ia proteins with collagen at sites of vascular injury allowing the arrest and activation of platelets (16). Following adhesion and activation, local platelet activating factors, including adenosine diphosphate (ADP), thromboxane A₂ (TXA₂), serotonin, collagen and thrombin, are released. These factors help to recruit additional circulating platelets, and also contribute to several distinct manifestations of platelet activation, including, independent of the stimulus, the same series of actions: i) change of shape from discoid to a pseudopodial structure due to mobilisation of signalling molecules within the platelet, especially calcium, diacylglycerol (DAG), and inositol 1,4,5-trisphosphate (IP3); ii) expression of pro-inflammatory molecules (e.g. P-selectin, soluble CD40 ligand and others); iii) secretory process of α -granules, dense bodies, and lysosomes; iv) disposal of arachidonic acid, which is rapidly converted to prostaglandins and lipoxygenase products; and v) conversion of the GPIIb/IIIa receptor into an active form, effectively allowing platelet aggregation (15, 17–19). The aggregation response is initiated when circulating platelets are exposed to agonists released by the plaque such as vWF and collagen. This triggers a signal promoting ion flux, protein kinase activation, cytoskeletal polymerisation, and arachidonic acid metabolism, resulting in conformational changes in the GP surface receptor IIB/IIIa (GPIIb/IIIa) to a ligand receptive state. Ligand receptive GPIIb/IIIa

bind fibrinogen which bridges adjacent platelets and facilitates aggregation (3, 20). These processes are followed by local activation of coagulation which may involve both the extrinsic and intrinsic pathways. Activation of the extrinsic pathway includes binding of tissue factor (TF) and factor VIIa (► Fig. 1) whilst activation of the intrinsic pathway encloses assembly of the intrinsic Xase complex consisting of activated factors VIIIa and IXa. Both processes give an enzymatically active 'tenase' complex which activates factors IX and X, leading to thrombin generation, fibrinogen and FXIII activation and fibrin clot formation (21, 22). TF is expressed at high levels in macrophages and SMCs within arteriosclerotic lesions (23–25) and is thought to have a major role in determining thrombogenicity of human arteriosclerotic lesions. In contrast plasma proteins in the presence of a phospholipid surface classically provided by platelets are known as the source for the intrinsic Xase complex (26). However, *in vitro*-work suggests that exposure of macrophages and SMCs to oxidised low-density lipoprotein (oxLDL) enhances their ability to support activity of the intrinsic pathway to increase plaque thrombogenicity (27). Together, these processes lead to the development of a platelet-rich thrombus which is stabilised via bridges formed by fibrinogen.

The common soil hypothesis, originally put forward by Stern, suggested that diabetes and CVD were essentially the same condition with common antecedents. Multiple factors such as insulin resistance, hyperglycaemia and oxidation products have been suggested to underpin this association, however in recent years low grade inflammation has emerged as a strong candidate involved in




Figure 1: The coagulation and fibrinolytic pathways. Activation of the coagulation cascade occurs through release of tissue factor (extrinsic pathway). This leads to the generation of thrombin which activates fibrinogen by cleavage of fibrinopeptides A and B resulting in polymerisation to form the fibrin clot. Factor XIIIa catalyses the formation of covalent cross-links between

fibrin molecules which enhances the stability of the clot. Fibrinolysis is initiated by the activation of plasminogen to plasmin by tissue-plasminogen activator (t-PA) and urinary-type plasminogen activator (u-PA). The main inhibitors of fibrinolysis are plasminogen activator inhibitor-1 (PAI-1) and α 2-antiplasmin.

Table 1: Effects of altered glycaemic control on platelet function.

Metabolic changes	Oxidative stress	Endothelial dysfunction
<ul style="list-style-type: none"> ● Thromboxane synthesis ↑ ● Sensitivity to agonists ↑ ● Activation of protein kinase C ● Nitric oxide production ↓ ● Superoxide formation ↑ ● Non-enzymatic glycation of platelet membrane proteins ● Expression of p-selectin and glycoprotein receptors ↑ ● Insulin sensitivity ↓ ● Reactive oxygen species (ROS) ↑ 	<ul style="list-style-type: none"> ● Platelet nitric oxide production ↑ ● Intracellular Ca²⁺ concentration ↑ ● Platelet membrane sodium-potassium-ATP activity ↓ ● Activation of protein kinase C and nuclear factor-κB ● Formation of 8-iso-prostaglandin F_{2α} 	<ul style="list-style-type: none"> ● Nitric oxide production ↓ ● Reactive oxygen species (ROS) ↑ ● Pro-inflammatory cytokines ↑ ● Platelet adhesion molecules ↑

the pathogenesis of both conditions (8). Inflammation can alter all the processes involved in the development of atherothrombosis. Early changes include endothelial dysfunction with decreased nitric oxide (NO) production. NO is a key player in negative regulation of platelet activity and decreased levels result in hyper-reactivity of platelets (28). Furthermore, cytokines produced by inflammatory cells, such as macrophages and T-lymphocytes, induce TF expression in endothelial cells, macrophages and SMCs, thereby enhancing the pro-thrombotic properties of the atherosclerotic plaque (29–31). The interaction between inflammation and coagulation is not limited to the site of vessel injury. Plasma levels of inflammatory markers are elevated in CVD (32) and correlate with incident diabetes (33–36). In obesity, which is associated with both diabetes and CVD, visceral adipose tissue is a major source for inflammatory activity. In overweight subjects adipose tissue contains activated T-lymphocytes (37) and macrophages (38, 39) which interact with adipocytes to produce inflammatory cytokines including interferon (IFN)- γ (40), monocyte chemoattractant protein (MCP)-1, tumour necrosis factor (TNF) α , interleukin (IL)-6, and the fibrinolytic inhibitor plasminogen activator inhibitor (PAI)-1 (41). The expression of these cytokines contributes to increased production of fibrinogen to induce, together with elevated PAI-1 levels, a pro-thrombotic milieu (35, 42–50).

In the following, the interaction between inflammatory processes and their relation to coagulation in diabetes will be described in more detail.

Platelet alterations

Activation and aggregation of platelets is one of the first steps following plaque rupture. In diabetes, platelet hyper-activation and hyper-aggregation plays a crucial role in thrombotic complications associated within this condition. In general, platelets are reported to respond more frequently to sub-threshold stimuli, becoming consumed more rapidly which results in an accelerated thrombopoiesis of fresh and hyper-reactive platelets in diabetes (51). This so called platelet dysfunction is related to several mechanisms including metabolic changes, oxidative stress and endothelial dysfunction (► Table 1) (52).

Metabolic changes

Hyperglycaemia, a diagnostic characteristic of diabetes, plays a causal role in platelet hyper-reactivity. Increased thromboxane synthesis is related to platelet hyper-reactivity and is tightly regulated by glucose control (53). Acute, short-term hyperglycaemia also induces increased activation of platelets exposed to high shear stress conditions (54) and leads to increased sensitivity to agonists due to activation of protein kinase C (PKC), decreased production of platelet-derived NO, and increased formation of superoxide (55, 56). In addition, Ca²⁺ homeostasis is known to be impaired in diabetes with an increase in calcium mobilisation from intracellular storage pools, resulting in increased intracellular Ca²⁺ levels. This is thought to be due to a change in the activity and the direction of the Na⁺/Ca²⁺ exchanger (57). Furthermore, hyperglycaemia results in non-enzymatic glycosylation (glycation) of platelet membrane proteins which may cause changes in protein structure and conformation. This may lead to alterations of the membrane lipid dynamics causing enhanced surface expression of P-selectin and GP receptors, leaving platelets more susceptible to activators (55, 58).

Increased platelet sensitivity to aggregation agents can also be explained by an effect of non-enzymatically glycated low-density lipoproteins (glycLDL), which renders platelets more susceptible to oxidative stress. Moreover, glycLDL may cause platelet dysfunction by an increase in intracellular Ca²⁺ concentration and platelet NO production, as well as inhibition of the platelet membrane Na⁺/K⁺-adenosine triphosphatase activity. Whilst increased Ca²⁺ concentrations are consistent with the enhanced platelet sensitivity to aggregation agents, the higher NO production is thought to be a result of the higher Ca²⁺ levels as the form of NO present in normal human platelets is Ca²⁺-calmodulin dependent (59). Furthermore, other changes of the lipid profile can be found in patients with diabetes mellitus including elevated triglycerides, decreased high-density lipoprotein (HDL) and increased small dense LDL levels. All of these may affect platelet function by decreasing membrane fluidity or directly interacting with the intracellular system (55).

Furthermore, platelets retain a functionally active insulin receptor (60). Insulin interacts with ADP- and thrombin-induced platelet functions through inference with the P2Y₁₂-mediated

regulation of G_i . After receptor binding, insulin activates the insulin receptor substrate-1 (IRS-1) through tyrosine phosphorylation, which initiates association with $G_i\alpha$ -subunit. This results in inhibition of $G_i\alpha$ activity and impaired suppression of cyclic adenosine monophosphate (cAMP), thus inhibiting $P2Y_{12}$ signalling and thereby reducing platelet reactivity (61). However, in the presence of diabetes platelets lose their responsiveness to insulin leading to increased adhesion, aggregation, and pro-coagulant activity (62).

Oxidative stress

Oxidative stress represents another modulator of platelet activation. Studies demonstrated that hyperglycaemia induces an increase in glycation of LDL, which renders platelets more susceptible to oxidative stress by increasing platelet NO production, intracellular Ca^{2+} concentration, and inhibiting platelet membrane sodium-potassium-ATP activity (59, 63). Furthermore, chronic hyperglycaemia may induce reactive oxygen species (ROS) production directly via glucose metabolism and auto-oxidation and indirectly through the formation of advanced glycation end products (AGEs) and their receptor binding. ROS activates signalling molecules within endothelial cells including PKC and nuclear factor- κ B leading to transcription of genes encoding pro-inflammatory and pro-thrombotic molecules (64). In addition, ROS leads to the formation of 8-iso-prostaglandin $F2_{\omega}$, a non-enzymatic oxidation product of circulating LDL and arachidonic acid, which induces vasoconstriction and platelet hyper-reactivity (65–67).

Endothelial dysfunction

Endothelial dysfunction plays a crucial role in the development of atherothrombosis. Endothelial cells produce mediators of vasodilatation (i.e. NO and prostacyclin) and vasoconstriction (i.e. angiotensin II and TXA) to regulate vascular tone and thrombotic processes. In diabetes, vasoconstrictive, pro-thrombotic effects dominate, and hyperglycaemia and insulin resistance play a crucial role by inhibiting NO production and increasing ROS production, leading to an increased expression of pro-inflammatory cytokines and platelet adhesion molecules (68). Apart from affecting platelet function these alterations may also alter coagulation and fibrinolysis to further contribute to an enhanced thrombotic milieu in diabetes.

The fluid phase of coagulation

A variety of studies have reported alterations in coagulation factors in relation to the metabolic milieu associated with insulin resistance and type 2 diabetes. Some, such as increased fibrinogen lev-

els appear to be initiated by an inflammatory profile, whilst activation of coagulation proteins such as factor VII and XII is enhanced by the presence of triglyceride rich particles. Hyperglycaemia itself can also modify coagulation processes through post translational modifications of protein structure/function.

Tissue factor

TF is the key initiator of the coagulation cascade which binds to factor VIIa leading to activation of factors IX and X resulting in thrombus formation (69). Both vascular and non-vascular cells are known to express TF including endothelial cells, SMCs, monocytes / macrophages, and platelets. Under physiological conditions endothelial cells express very little TF (70). However, after stimulation with cytokines including $TNF\alpha$ (71), $IL-1\beta$ (72), or mediators such as histamine (73), thrombin (74) or oxLDL (75), TF expression is increased. In contrast, SMCs constitutively express TF and in arteriosclerosis SMCs and macrophages are known to express TF at high levels (23–25, 76, 77). Monocytes are the major source of vascular cells expressing TF (78). Similarly to endothelial cells, basal expression levels are low but upon stimulation expression increases significantly (79–82). However the role of platelets as a possible source for TF within the circulation is controversial. Butenas et al. were not able to detect TF activity on activated platelets (83), whilst in contrast other studies showed functionally active TF in platelets with exposure on the cell surface following activation (84–86).

In diabetes, TF levels are elevated (87) partly in relation to underlying low grade inflammation. In obesity, adipose tissue functions as a site of TF production due to the release of TF by adipocytes and resident inflammatory macrophages in the stromavascular fraction (88). Clamp studies demonstrated that hyperglycaemia results in elevated TF levels regardless of insulin concentration (89) and both AGEs and ROS are also able to increase TF level (70, 90). A recent study by Gerrits et al. demonstrated that insulin can inhibit TF synthesis in normal platelets whereas insulin inhibition is lost in platelets from patients with type 2 diabetes resulting in 1.6 fold higher TF expression (91).

Factor VII

TF binds and activates factor VII (FVII) resulting in activation of the coagulation cascade. More than 20 years ago the Northwick Park Heart study associated high levels of FVII coagulant activity with an increased risk for ischaemic heart disease (92). Since then studies have both confirmed (93) and contradicted this original finding (94–96). Elevated levels of FVII:c have been associated with the metabolic syndrome in otherwise healthy individuals (97, 98). In first-degree relatives of patients with diabetes, who are known to have an elevated risk for the development of diabetes and CVD, FVII:c levels are elevated and cluster with other risk factors

associated with insulin resistance (99). However a study of diabetes patients and age and obesity matched controls demonstrated lower FVII:c and FVII antigen levels in diabetes compared to healthy controls, suggesting that increased FVII:c and FVII antigen levels are more related to body mass index and age than diabetes (100). A recent report by Karatela and Sainani could not confirm the association between FVII coagulant activity and obesity, but strengthens a positive correlation between FVII:c levels and plasma triglycerides, which are known to be elevated in insulin resistant diabetes (101–103).

Von Willebrand factor and factor VIII

vWF is selectively expressed in endothelial cells and platelets. It has two major functions: i) to promote platelet adhesion to the vascular wall following endothelial damage and ii) vWF serves as a carrier protein in the plasma for FVIII, stabilising it within the circulation and increasing the half life of FVIII. Low levels of vWF are associated with a platelet bleeding disorder, whilst FVIII is the protein deficient in classical haemophilia. Elevated levels of vWF and FVIII have been related to cardiovascular risk, although it is likely that this occurs in concert with other risk factors. Expression of vWF is regulated by a number of agonists including thrombin, complement components, histamine and numerous other mediators (104). Some of these agonists have an inflammatory component to their effect, linking elevated vWF to this aspect of the diabetes state. Many studies have demonstrated an association between elevated vWF and / or FVIII levels and CVD, but in most this association was lost after adjusting for common cardiovascular risk factors (95, 105, 106). However, elevated vWF and FVIII levels correlate with diabetes (107) and in such patients the association between vWF / FVIII levels and CVD persisted even after adjustment for traditional risk factors (108–110). Several cytokines, including TNF α and IL-6 are known to stimulate vWF expression from endothelial cells and CRP as a marker for low grade inflammation has been shown to be associated with elevated vWF levels, which could be one mechanism by which diabetes affects vWF levels (106, 111).

Fibrinogen

Fibrinogen is a heterodimer composed of three pairs of non-identical polypeptide chains, A α , B β and γ (112). It is synthesised by the liver and plasma levels influence thrombogenesis (113). It has been widely accepted that fibrinogen is strongly and independently related to CVD (114), and in diabetes fibrinogen may also contribute to increased cardiovascular risk. Fibrinogen undergoes glycation in the presence of poor glucose control (115, 116), which can influence the function of fibrinogen leading to the formation of a tight and rigid fibrin network (117, 118). This has previously been shown to be associated with an increased risk for MI (119, 120).

These changes seem to alter interactions with other fibrinolytic proteins to alter plasmin generation on the clot surface and slow lysis which may contribute to cardiovascular risk (115). In addition, studies demonstrated a decrease in fibrinogen glycation and an increase in the proportion of fibre thickness after improving glycaemic control (121, 122). Fibrinogen levels are elevated in diabetes patients (123), a response which occurs for a variety of reasons. A number of polymorphisms have been associated with increased fibrinogen levels (124, 125), however, the inflammatory state in diabetes can also influence fibrinogen levels. In adipose tissue, macrophages produce cytokines including IL-6, IL-1 and TNF α which, after reaching the circulation, may induce the production of acute phase proteins such as fibrinogen by the liver (123, 126, 127).

Factor XIII

Coagulation FXIII is a tetrameric pro-transglutaminase that consists of two A and B subunits and which, when activated by thrombin, has a crucial role in cross-linking a fibrin clot to provide a structure which has a rigid structure resistant to clot lysis. Under normal conditions FXIII-A is found only as a complex with the B subunit in plasma. The B subunit serves as a carrier protein for the A subunit and is found in excess in plasma, with 50% circulating as free molecules (128). Following activation by thrombin the A subunit is cleaved from the B subunit in a reaction facilitated by calcium and fibrin, releasing the active site of FXIII-A and catalysing cross-linking between the α and γ chain of fibrin, to stabilise clot structure. A role for FXIII in CVD was initially demonstrated by Kohler et al. and confirmed by others, showing that the FXIII-A Val34Leu polymorphism provides a protective effect from MI (128, 129). In diabetes, FXIII levels have been shown to be elevated, whereas FXIII cross-linking activity was not different compared to controls. Factor XIII B subunit levels correlated with features of the metabolic syndrome both in diabetes patients, their first degree relatives and healthy south Asian subjects (130, 131). The absence of an association between the FXIII A subunit and the insulin resistance syndrome may reflect the different site of synthesis with the A subunit, which is produced by haematopoietic cells and the B subunit by hepatocytes (113).

Fibrinolysis

Numerous studies have reported suppression of fibrinolysis in insulin resistant type 2 diabetes and it is thought that this is related to elevated levels of the fibrinolytic inhibitor PAI-1 and that these changes may contribute to cardiovascular risk. Other work has characterised the effects of fibrin(ogen) glycation on resistance to lysis, with evidence of changes in clot structure that decrease plasmin generation and slow lysis (115). Furthermore, more recent data show that complement C3 is expressed from visceral adipose

tissue of type 2 diabetic subjects (132), and we and others (133) have demonstrated C3 to be present in a fibrin clot and to have a role in thrombus formation in patients with MI. Our recent *in vitro*-experiments revealed that C3 binds to fibrin with tight affinity and prolongs clot lysis time in control subjects with further increases in the presence of diabetes (unpublished data, [134, 135]), directly interacting with fibrinolysis to influence the pro-thrombotic milieu.

Plasminogen activator inhibitor

PAI-1 belongs to the serine protease inhibitor (serpin) superfamily. It is a single chain GP which can be secreted from a variety of cells including hepatocytes, vascular endothelial cells, SMCs, adipocytes and platelets (136). It is responsible for the regulation of the fibrinolytic system by rapid formation of inactive complexes with its target serine proteases, tissue-type (t-PA) and urokinase-type (u-PA) plasminogen activators to prevent plasmin generation and thereby fibrin(ogen)olysis (137, 138). Various studies have shown that PAI-1 levels are elevated in CVD (139, 141). In diabetes PAI-1 levels are increased and independently associated with cardiovascular risk (48, 142, 143). Furthermore, various studies demonstrated an association of PAI-1 with features of the metabolic syndrome, including body mass index, blood pressure, plasma triglycerides and insulin levels in both healthy individuals and patients with diabetes (48, 144, 145). The liver is thought to be the major source for PAI-expression. PAI-1 is an acute phase reactant and cytokines can alter plasma levels by induction of expression in the liver (146). Similarly, insulin, very-low density lipoproteins and free fatty acids stimulate PAI-1 expression (147). In addition to the liver, adipocytes are known to express PAI-1 and levels are elevated in obesity (148). Macrophages play an important role in this process as they can produce PAI-1 themselves (149) and macrophage cytokines such as TNF α stimulate PAI-1 production in adipose tissue (150). Furthermore, studies of human adipocytes and adipose tissue explants have reported that insulin induces PAI-1 production in adipocytes (151). However, a single stimulus *in vivo* may be insufficient to result in increased PAI-1 concentrations but several stimuli as present in diabetic state are required (152, 153).

Tissue plasminogen activator


t-PA is a single chain active serine protease and is synthesised by endothelial cells. Under physiological conditions t-PA activates plasminogen at a very slow rate. After formation of a fibrin clot both t-PA and plasminogen bind to fibrin resulting in a 1,000-fold enhanced catalytic activity of t-PA (154). Clinical studies have found an association of t-PA with components of the metabolic syndrome (155, 156) and levels were higher in subjects with glucose intolerance compared to healthy individuals (157). Similarly, other clinical studies demonstrated an elevation of t-PA levels in

diabetes patients (158, 159). Given that t-PA is responsible for fibrinolysis of fibrin clots one would expect a beneficial effect of elevated plasma levels. However, several studies demonstrated an association between elevated t-PA levels and CVD (160–163). PAI-1 and t-PA levels have found to be strongly associated, with both forming complexes within circulation (164), and elevated t-PA levels may reflect raised PAI-1 levels in insulin resistance and diabetes.

Strategies to reduce thrombotic risk in diabetes

In summary, patients with diabetes feature an increased pro-thrombotic risk related to complex interactions between the fluid (complement, coagulation/fibrinolysis) and cellular (macrophage, platelet) phases of inflammatory and thrombotic processes. These interactions promote all phases of vascular damage from early endothelial dysfunction through to plaque formation, rupture and occlusive thrombus formation. The specific changes in thrombus formation generates a platelet-rich clot which is more compact, resistant to lysis and associated with increased cardiovascular risk (► Fig. 2) (119, 120). Current guidelines for primary prevention of CVD in people with diabetes mellitus by the American Heart and Diabetes association (165) recommend, beside general lifestyle modifications, the therapy of overall cardiovascular risk factors, which include management of high blood pressure and elevated lipids. In addition glycaemic control is important and the HbA1c goal in general is <7% with an individual goal as close to normal (<6%) as possible without causing significant hypoglycaemia (165). However, lowering of HbA1c has only a modest effect on cardiovascular risk reduction in diabetes patients (166). Therefore, to prevent CVD oral anti-diabetic agents (OADs) should ideally lower blood glucose and address the cardiovascular risk cluster; an aspect of management which is reviewed comprehensively elsewhere (167). Briefly, some of the OADs exhibit favourable effects on the pro-thrombotic profile. As demonstrated by the UK prospective Diabetes Study (UKPDS), metformin reduced the risk of ischaemic heart disease compared to other hypoglycaemic agents (168). This may be explained as metformin affects the coagulation system by inhibiting platelet aggregation and reducing levels of fibrinogen, factor VII and PAI-1. Furthermore, clots formed in the presence of metformin lyse more quickly suggesting a direct effect on clot structure (169, 170). Relatively little is known about the role of sulphonylureas on the thrombotic profile. However, studies demonstrated that they exert anti-platelet activity (171, 172) and reduce PAI-1 levels (173). Thiazolidinediones show similar effects on both platelets and PAI-1 levels (174–176). Furthermore, clinical studies demonstrated that glitazones can delay progression of atherothrombotic lesions (177), although outcome studies have been disappointing. In the PROactive trial, pioglitazone failed to reach the primary end point (all-cause mortality, non-fatal silent and non-silent MI, stroke, acute coronary syndrome, cardiac revascularisation, major leg amputation or leg re-vascularisation) but

Figure 2: Components of the pro-thrombotic risk cluster in diabetes mellitus. The presence of these alterations leads to the development of a compact and dense clot structure which is more difficult to lyse and associated with an increased cardiovascular risk. FVII:c: factor VII; vWF: von Willebrand factor; FVIII: factor VIII, FXIII: factor XIII, PAI-1: plasminogen activator-inhibitor-1; t-PA: tissue-plasminogen activator.



was positive for pre-specified secondary endpoint (all-cause mortality, non-fatal MI and stroke), suggesting that treatment with this agent either reduces cardiovascular events in diabetes or is simply neutral (178). In contrast, a meta-analysis by Nissen et al. suggested that rosiglitazone increases the risk of cardiovascular events in diabetes (179). However, the recent RECORD trial demonstrated this not to be the case, although it failed to show a reduction in cardiovascular events in rosiglitazone users (180). In addition the guidelines recommend the use of aspirin (75 to 162 mg / d) for patients with diabetes who are at increased cardiovascular risk, including most men over the age of 50 and women over age 60 years or who have one or more additional risk factor(s) such as a family history of CVD, hypertension, smoking, dyslipidaemia or albuminuria (165, 181). Aspirin selectively acetylates cyclooxygenase-1 (COX-1), thereby blocking the formation of TXA₂ in platelets. This effect is irreversible as platelets are enucleated and therefore can't re-synthesise COX-1. However, anti-platelet therapy in diabetes is still a matter of intense debate due to a high prevalence of hypo-responsiveness (182) and concerns over its effectiveness in primary prevention of CVD. So-called aspirin resistance assessed by an in vitro-platelet test has been reported in almost 20% of diabetes patients (183). Reduced susceptibility of various platelet proteins and receptors on the platelet surface to acetylation due to glycation might be one reason for this phenomenon (182). However, it remains unclear whether improved glycaemic control enhances the efficacy of aspirin, or increased doses are beneficial in aspirin resistance (58). In addition, evaluating aspirin resistance is difficult because there is no standardised method available. Various studies used different assays, agonists, cut-off values, and patient populations, making interpretation of the data and generalisation in clinical practice difficult. The ASPECT study demonstrated that the assessment of aspirin resistance is highly assay-dependent. Aspirin is an effective blocker of arachidonic acid-induced platelet

function at all doses, whereas higher estimates of resistance were observed with methods that do not use arachidonic acid as the stimulus (184, 185). In addition to its action on platelets, aspirin may directly alter clot structure resulting in the formation of clots with thicker fibres and bigger pores which are easier to lyse (186, 187). Further studies are needed to elucidate whether these effects are altered in diabetes.

Clopidogrel, a selective, irreversible antagonist of the platelet P2Y₁₂ ADP receptor, is the other most commonly used anti-platelet agent. There is emerging evidence that clopidogrel may be an alternative choice in patients with diabetes. The Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) trial examined the effects of clopidogrel (75 mg / day) versus aspirin (325 mg / day) in a large secondary prevention population including approximately 20 % patients with diabetes mellitus. The retrospective analysis of diabetic patients revealed that significantly more patients on aspirin treatment (17.7 %) reached the composite vascular primary endpoint compared to those randomised to clopidogrel (15.6 %) (188, 189) However, similarly to aspirin, studies report clopidogrel resistance which also varies due to the definitions used, the type of assay, dose of clopidogrel and the patient population. Nonetheless, clopidogrel non-responsiveness is more prevalent in patients with diabetes mellitus (190–193). In particular, type 2 diabetes patients undergoing elective PCI have approximately a four-fold increase in the number of non-responders at 24 hours, following a standard 300 mg loading dose (190). One explanation for these findings may be up-regulation of the P2Y₁₂ pathway due to insulin resistance of platelets in the diabetes state (58). These data point out the need for alternative and more potent anti-platelet agents. There are several P2Y₁₂ receptor-antagonists under investigation. These include the irreversible agent prasugrel and the reversible antagonist ticagrelor. A subanalysis of the trial to Assess Improvement in Therapeutic Outcomes by Optimizing Pla-

telet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38) showed, that subjects with diabetes tended to have a greater reduction in ischaemic events (HR 0.70) without an observed increase in major bleeding rates and therefore a greater net benefit with prasugrel compared to clopidogrel (194). In contrast, the PLATelet inhibition and patient outcome (PLATO) trial demonstrated, that ticagrelor, when compared to clopidogrel, reduced ischaemic events in acute coronary syndrome patients irrespective of diabetes status and glycaemic control, without an increase in major bleeding (195).

In addition to the anti-atherothrombotic properties of these agents some also exert an impact on underlying low grade inflammation. In general, life style intervention, particularly weight loss results in a decrease in inflammatory proteins (196, 197), thereby improving insulin resistance and the pro-thrombotic milieu. Thiazolidinediones, peroxisome proliferator-activated receptor- γ (PPAR γ) agonists, which primarily act on adipocytes but also on macrophages (198), are well known to decrease inflammatory molecules including CRP, TNF α and IL-6 independent of improvements of insulin sensitivity (32, 199). Similarly, metformin has favourable effects on some inflammatory markers such as CRP. However, this effect is not as pronounced as CRP reduction following weight reduction or treatment with PPAR α agonists (200). Statins, which are used to reduce the overall cardiovascular risk in these patients, are recognised to exert anti-inflammatory properties, characterised by a reduction of high sensitivity-CRP and a decrease of inflammatory cells within the arteriosclerotic plaque (201). The anti-inflammatory properties of thiazolidinediones, metformin and statins are side effects of their primary mode of action. In contrast, high dose aspirin directly inhibits inflammation and the glucose lowering effects of salicylates, described more than a century ago, are thought to be due to this mode of action (202–204).

Conclusion and future directions

Patients with diabetes are at increased risk of morbidity and mortality from CVD. Athero-thrombosis is a complex disease promoted by inflammatory thrombotic interactions which increase risk of occlusive arterial disease. In insulin resistant type 2 diabetes and in long standing type 1 diabetes, the fluid and cellular phases of inflammation and thrombus formation are up regulated leading to further increased risk of arterial disease. The importance of thrombus formation in the pathogenesis of, and outcome from, acute coronary syndromes emphasises the need for further understanding of the mechanisms underpinning the effects of the metabolic milieu associated with the presence of diabetes. There is an urgent need for clinical studies of carefully phenotyped patients with diabetes to establish the optimum anti-thrombotic regimes for the management of acute coronary syndromes and for the primary and secondary prevention of CVD in this population.

Acknowledgement

Katharina Hess is supported by a grant from the Deutsche Forschungsgemeinschaft (DFG-HE 5666/1–1).

Conflict of interest

None declared.

References

1. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. *Diabetes Care* 2004; 27: 1047–1053.
2. Garcia MJ, McNamara PM, Gordon T, et al. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. *Diabetes* 1974; 23: 105–111.
3. Stratmann B, Tschöep D. Atherogenesis and atherothrombosis—focus on diabetes mellitus. *Best Pract Res Clin Endocrinol Metab* 2009; 23: 291–303.
4. Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. *N Engl J Med* 1998; 339: 229–234.
5. Malmberg K, Yusuf S, Gerstein HC, et al. Impact of Diabetes on Long-Term Prognosis in Patients With Unstable Angina and Non-Q-Wave Myocardial Infarction Results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. *Circulation*. 2000; 102: 1014–1019.
6. Donahoe SM, Stewart GC, McCabe CH, et al. Diabetes and mortality following acute coronary syndromes. *J Am Med Assoc* 2007; 298: 765–775.
7. Reaven GM. Role of insulin resistance in human disease. *Diabetes* 1988; 37: 1595–1607.
8. Stern MP. Diabetes and cardiovascular disease. The „common soil“ hypothesis. *Diabetes* 1995; 44: 369–374.
9. Herder C, Haastert B, Müller-Scholze S, et al. Association of systemic chemokine concentrations with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg Survey S4 (KORA S4). *Diabetes* 2005; 54: 11–17.
10. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. *J Clin Invest* 2005; 115: 1111–1119.
11. Goldberg RB. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. *J Clin Endocrinol Metab* 2009; 94: 3171–3182.
12. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. *J Am Coll Cardiol* 2009; 54: 2129–2138.
13. Hansson GK. Inflammatory mechanisms in atherosclerosis. *J Thromb Haemost* 2009; 7 (Suppl 1): 328–331.
14. Shah PK. Inflammation and plaque vulnerability. *Cardiovasc Drugs Ther* 2009; 23: 31–40.
15. Angiolillo DJ, Ueno M, Goto S. Basic principles of platelet biology and clinical implications. *Circ J* 2010; 74: 597–607.
16. Varga-Szabo D, Pleines I, Nieswandt B. Cell adhesion mechanisms in platelets. *Arterioscler Thromb Vasc Biol* 2008; 28: 403–412.
17. Willoughby S, Holmes A, Loscalzo J. Platelets and cardiovascular disease. *Eur J Cardiovasc Nurs* 2002; 1: 273–288.
18. Leberer C, Sanmiguel J, Wilson JM, et al. Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent. *Cardiovasc Diabetol* 2007; 6: 15.
19. Offermanns S. Activation of platelet function through G protein-coupled receptors. *Circ Res* 2006; 99: 1293–1304.
20. Lefkowitz J, Plow E, Topol E. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. *N Engl J Med* 1995; 332: 1553–1559.
21. Banner DW, D'Arcy A, Chène C, et al. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. *Nature* 1996; 380: 41–46.
22. Saenko EL, Shima M, Sarafanov AG. Role of activation of the coagulation factor VIII in interaction with vWf, phospholipid, and functioning within the factor Xase complex. *Trends Cardiovasc Med* 1999; 9: 185–192.
23. Moreno PR, Bernardi VH, López-Cuellar J, et al. Macrophages, smooth muscle cells, and tissue factor in unstable angina. Implications for cell-mediated thrombogenicity in acute coronary syndromes. *Circulation* 1996; 94: 3090–3097.
24. Ardissino D, Merlini PA, Bauer KA, et al. Thrombogenic potential of human coronary atherosclerotic plaques. *Blood* 2001; 98: 2726–2729.

25. Schechter AD, Giesen PL, Taby O, et al. Tissue factor expression in human arterial smooth muscle cells. TF is present in three cellular pools after growth factor stimulation. *J Clin Invest* 1997; 100: 2276–2285.
26. Khrenov AV, Ananyeva NM, Griffin JH, et al. Coagulation pathways in atherothrombosis. *Trends Cardiovasc Med* 2002; 12: 317–324.
27. Ananyeva NM, Kouiavskaja DV, Shima M, et al. Intrinsic pathway of blood coagulation contributes to thrombogenicity of atherosclerotic plaque. *Blood* 2002; 99: 4475–4485.
28. Anderson TJ. Nitric oxide, atherosclerosis and the clinical relevance of endothelial dysfunction. *Heart Fail Rev* 2003; 8: 71–86.
29. Tousoulis D, Davies G, Stefanadis C, et al. Inflammatory and thrombotic mechanisms in coronary atherosclerosis. *Heart* 2003; 89: 993–997.
30. Levi M, van der Poll T. Inflammation and coagulation. *Crit Care Med* 2010; 38: S26–34.
31. Cirillo P, Golino P, Calabrò P, et al. C-reactive protein induces tissue factor expression and promotes smooth muscle and endothelial cell proliferation. *Cardiovasc Res* 2005; 68: 47–55.
32. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. *Circ Res* 2005; 96: 939–949.
33. Schmidt MI, Duncan BB, Sharrett AR, et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. *Lancet* 1999; 353: 1649–1652.
34. Duncan BB, Schmidt MI, Pankow JS, et al. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. *Diabetes* 2003; 52: 1799–1805.
35. Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. *J Am Med Assoc* 2001; 286: 327–334.
36. Festa A, D'Agostino RJ Jr, Tracy RP, et al. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. *Diabetes* 2002; 51: 1131–1137.
37. Kintscher U, Hartge M, Hess K, et al. T-lymphocyte infiltration in visceral adipose tissue: a primary event in adipose tissue inflammation and the development of obesity-mediated insulin resistance. *Arterioscler Thromb Vasc Biol* 2008; 28: 1304–1310.
38. Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. *J Clin Invest* 2003; 112: 1796–1808.
39. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. *J Clin Invest* 2003; 112: 1821–1830.
40. Rocha VZ, Folco EJ, Sukhova G, et al. Interferon-gamma, a Th1 cytokine, regulates fat inflammation: a role for adaptive immunity in obesity. *Circ Res* 2008; 103: 467–476.
41. Suganami T, Nishida J, Ogawa Y. A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. *Arterioscler Thromb Vasc Biol* 2005; 25: 2062–2068.
42. Rosenson RS, Koenig W. Utility of inflammatory markers in the management of coronary artery disease. *Am J Cardiol* 2003; 92: 10i–18i.
43. Ajjan R, Grant PJ, Futers TS, et al. Complement C3 and C-reactive protein levels in patients with stable coronary artery disease. *Thromb Haemost* 2005; 94: 1048–1053.
44. Ajjan RA, Ariens RA. Cardiovascular disease and heritability of the prothrombotic state. *Blood Rev* 2009; 23: 67–78.
45. Barzilay JI, Abraham L, Heckbert SR, et al. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. *Diabetes* 2001; 50: 2384–2389.
46. Freeman DJ, Norrie J, Caslake MJ, et al. West of Scotland Coronary Prevention Study. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. *Diabetes* 2002; 51: 1596–1600.
47. Spranger J, Kroke A, Möhlig M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. *Diabetes* 2003; 52: 812–817.
48. Juhan-Vague I, Roul C, Alessi MC, et al. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients--relationship with plasma insulin. *Thromb Haemost* 1989; 61: 370–373.
49. Collier A, Rumley A, Rumley A, et al. Free radical activity and hemostatic factors in NIDDM patients with and without microalbuminuria. *Diabetes* 1992; 41: 909–913.
50. McGill JB, Schneider DJ, Arfken CL, et al. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. *Diabetes* 1994; 43: 104–109.
51. Watala C. Blood platelet reactivity and its pharmacological modulation in (people with) diabetes mellitus. *Curr Pharm Des* 2005; 11: 2331–2365.
52. Colwell JA, Nesto RW. The platelet in diabetes: focus on prevention of ischemic events. *Diabetes Care* 2003; 26: 2181–2188.
53. Davì G, Catalano I, Averna M, et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. *N Engl J Med* 1990; 322: 1769–1774.
54. Gresele P, Guglielmini G, De Angelis M, et al. Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus. *J Am Coll Cardiol* 2003; 41: 1013–1020.
55. Ferroni P, Basili S, Falco A, et al. Platelet activation in type 2 diabetes mellitus. *J Thromb Haemost* 2004; 2: 1282–1291.
56. Assert R, Scherck G, Bumbure A, et al. Regulation of protein kinase C by short term hyperglycaemia in human platelets in vivo and in vitro. *Diabetologia* 2001; 44: 188–195.
57. Li Y, Woo V, Bose R. Platelet hyperactivity and abnormal Ca(2+) homeostasis in diabetes mellitus. *Am J Physiol Heart Circ Physiol* 2001; 280: H1480–1489.
58. Angiolillo DJ, Suryadevara S. Aspirin and clopidogrel: efficacy and resistance in diabetes mellitus. *Best Pract Res Clin Endocrinol Metab* 2009; 23: 375–388.
59. Ferretti G, Rabini RA, Bacchetti T, et al. Glycated low density lipoproteins modify platelet properties: a compositional and functional study. *J Clin Endocrinol Metab* 2002; 87: 2180–2184.
60. Falcon C, Pfliegler G, Deckmyn H, et al. The platelet insulin receptor: detection, partial characterization, and search for a function. *Biochem Biophys Res Commun* 1988; 157: 1190–1196.
61. Ferreira IA, Eybrechts KL, Mocking AI, et al. IRS-1 mediates inhibition of Ca²⁺ mobilization by insulin via the inhibitory G-protein Gi. *J Biol Chem* 2004; 279: 3254–3264.
62. Ferreira IA, Mocking AI, Feijge MA, et al. Platelet inhibition by insulin is absent in type 2 diabetes mellitus. *Arterioscler Thromb Vasc Biol* 2006; 26: 417–422.
63. Kobayashi K, Watanabe J, Umeda F, et al. Glycation accelerates the oxidation of low density lipoprotein by copper ions. *Endocr J* 1995; 42: 461–465.
64. Ha H, Lee HB. Oxidative stress in diabetic nephropathy: basic and clinical information. *Curr Diab Rep* 2001; 1: 282–287.
65. Patrono C, FitzGerald GA. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. *Arterioscler Thromb Vasc Biol* 1997; 17: 2309–2315.
66. Davì G, Falco A, Patrono C. Determinants of F2-isoprostane biosynthesis and inhibition in man. *Chem Phys Lipids* 2004; 128: 149–163.
67. Praticò D, Smyth EM, Violi F, et al. Local amplification of platelet function by 8-Epi prostaglandin F2alpha is not mediated by thromboxane receptor isoforms. *J Biol Chem* 1996; 271: 14916–14924.
68. De Vriese AS, Verbeuren TJ, Van de Voorde J, et al. Endothelial dysfunction in diabetes. *Br J Pharmacol* 2000; 130: 963–974.
69. Owens AP, Mackman N. Tissue factor and thrombosis: The clot starts here. *Thromb Haemost* 2010; 104: 432–439.
70. Breitenstein A, Tanner FC, Lüscher TF. Tissue factor and cardiovascular disease. *Circ J* 2010; 74: 3–12.
71. Steffel J, Hermann M, Greutert H, et al. Celecoxib decreases endothelial tissue factor expression through inhibition of c-Jun terminal NH2 kinase phosphorylation. *Circulation* 2005; 111: 1685–1689.
72. Napoleone E, Di Santo A, Lorenzet R. Monocytes upregulate endothelial cell expression of tissue factor: a role for cell-cell contact and cross-talk. *Blood* 1997; 89: 541–549.
73. Steffel J, Akhmedov A, Greutert H, et al. Histamine induces tissue factor expression: implications for acute coronary syndromes. *Circulation* 2005; 112: 341–349.
74. Eto M, Kozai T, Cosentino F, et al. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. *Circulation* 2002; 105: 1756–1759.
75. Drake TA, Hannani K, Fei HH, et al. Minimally oxidized low-density lipoprotein induces tissue factor expression in cultured human endothelial cells. *Am J Pathol* 1991; 138: 601–607.
76. Camici GG, Steffel J, Akhmedov A, et al. Dimethyl sulfoxide inhibits tissue factor expression, thrombus formation, and vascular smooth muscle cell activation: a potential treatment strategy for drug-eluting stents. *Circulation* 2006; 114: 1512–1521.

77. Wu J, Stevenson MJ, Brown JM, et al. C-reactive protein enhances tissue factor expression by vascular smooth muscle cells: mechanisms and in vivo significance. *Arterioscler Thromb Vasc Biol* 2008; 28: 698–704.
78. Shantsila E, Lip GY. The role of monocytes in thrombotic disorders. Insights from tissue factor, monocyte-platelet aggregates and novel mechanisms. *Thromb Haemost* 2009; 102: 916–924.
79. Song CJ, Nakagomi A, Chandar S, et al. C-reactive protein contributes to the hypercoagulable state in coronary artery disease. *J Thromb Haemost* 2006; 4: 98–106.
80. Chung J, Koyama T, Ohsawa M, et al. 1,25(OH)(2)D(3) blocks TNF-induced monocyte tissue factor expression by inhibition of transcription factors AP-1 and NF-kappaB. *Lab Invest* 2007; 87: 540–547.
81. Cai H, Song C, Endoh I, et al. Serum amyloid A induces monocyte tissue factor. *J Immunol* 2007; 178: 1852–1860.
82. Celi A, Del Fiorentino A, Cianchetti S, et al. Tissue factor modulation by Angiotensin II: a clue to a better understanding of the cardiovascular effects of renin-angiotensin system blockade? *Endocr Metab Immune Disord Drug Targets* 2008; 8: 308–313.
83. Butenas S, Bouchard BA, Brummel-Ziedins KE, et al. Tissue factor activity in whole blood. *Blood* 2005; 105: 2764–2770.
84. Zillmann A, Luther T, Müller I, et al. Platelet-associated tissue factor contributes to the collagen-triggered activation of blood coagulation. *Biochem Biophys Res Commun* 2001; 281: 603–609.
85. Müller I, Klocke A, Alex M, et al. Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets. *FASEB J* 2003; 17: 476–478.
86. Panes O, Matus V, Sáez CG, et al. Human platelets synthesize and express functional tissue factor. *Blood* 2007; 109: 5242–5250.
87. Boden G, Vaidyula VR, Homko C, et al. Circulating tissue factor procoagulant activity and thrombin generation in patients with type 2 diabetes: effects of insulin and glucose. *J Clin Endocrinol Metab* 2007; 92: 4352–4358.
88. Samad F, Pandey M, Loskutoff DJ. Tissue factor gene expression in the adipose tissues of obese mice. *Proc Natl Acad Sci USA* 1998; 95: 7591–7596.
89. Stegenga ME, van der Crabben SN, Levi M, et al. Hyperglycemia stimulates coagulation, whereas hyperinsulinemia impairs fibrinolysis in healthy humans. *Diabetes* 2006; 55: 1807–1812.
90. Min C, Kang E, Yu S, et al. Advanced glycation end products induce apoptosis and procoagulant activity in cultured human umbilical vein endothelial cells. *Diabetes Res Clin Pract* 1999; 46: 197–202.
91. Gerrits AJ, Koekman CA, van Haefen TW, et al. Platelet tissue factor synthesis in type 2 diabetes patients is resistant to inhibition by insulin. *Diabetes* 2010; 59: 1487–1495.
92. Meade TW, Mellows S, Brozovic M, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. *Lancet* 1986; 2: 533–537.
93. Kario K, Miyata T, Sakata T, et al. Fluorogenic assay of activated factor VII. Plasma factor VIIa levels in relation to arterial cardiovascular diseases in Japanese. *Arterioscler Thromb* 1994; 14: 265–274.
94. Heinrich J, Balleisen L, Schulte H, et al. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. *Arterioscler Thromb* 1994; 14: 54–59.
95. Folsom AR, Wu KK, Rosamond WD, et al. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. *Circulation* 1997; 96: 1102–1108.
96. Green D, Foiles N, Chan C, et al. Elevated fibrinogen levels and subsequent subclinical atherosclerosis: the CARDIA Study. *Atherosclerosis* 2009; 202: 623–631.
97. Balleisen L, Assmann G, Bailey J, et al. Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population--II. Baseline data on the relation to blood pressure, blood glucose, uric acid, and lipid fractions. *Thromb Haemost* 1985; 54: 721–723.
98. Balleisen L, Bailey J, Epping PH, et al. Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population: I. Baseline data on the relation to age, gender, body-weight, smoking, alcohol, pill-using, and menopause. *Thromb Haemost* 1985; 54: 475–479.
99. Mansfield MW, Heywood DM, Grant PJ. Circulating levels of factor VII, fibrinogen, and von Willebrand factor and features of insulin resistance in first-degree relatives of patients with NIDDM. *Circulation* 1996; 94: 2171–2176.
100. Vambergue A, Rugeri L, Gaveriaux V, et al. Factor VII, tissue factor pathway inhibitor, and monocyte tissue factor in diabetes mellitus: influence of type of diabetes, obesity index, and age. *Thromb Res* 2001; 101: 367–375.
101. Karatela RA, Sainani GS. Interrelationship between coagulation factor VII and obesity in diabetes mellitus (type 2). *Diabetes Res Clin Pract* 2009; 84: e41–44.
102. Heywood DM, Mansfield MW, Grant PJ. Factor VII gene polymorphisms, factor VII: C levels and features of insulin resistance in non-insulin-dependent diabetes mellitus. *Thromb Haemost* 1996; 75: 401–406.
103. Bruckert E, Carvalho de Sousa J, Giral P, et al. Interrelationship of plasma triglyceride and coagulant factor VII levels in normotriglyceridemic hypercholesterolemia. *Atherosclerosis* 1989; 75: 129–134.
104. Vischer UM. von Willebrand factor, endothelial dysfunction, and cardiovascular disease. *J Thromb Haemost* 2006; 4: 1186–1193.
105. Rumley A, Lowe GD, Sweetnam PM, et al. Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart Study. *Br J Haematol* 1999; 105: 110–116.
106. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. *N Engl J Med* 2004; 350: 1387–1397.
107. Conlan MG, Folsom AR, Finch A, et al. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. *Thromb Haemost* 1993; 70: 380–385.
108. Saito I, Folsom AR, Brancati FL, et al. Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. *Ann Intern Med* 2000; 133: 81–91.
109. Frankel DS, Meigs JB, Massaro JM, et al. Von Willebrand factor, type 2 diabetes mellitus, and risk of cardiovascular disease: the framingham offspring study. *Circulation* 2008; 118: 2533–2539.
110. Kistorp C, Chong AY, Gustafsson F, et al. Biomarkers of endothelial dysfunction are elevated and related to prognosis in chronic heart failure patients with diabetes but not in those without diabetes. *Eur J Heart Fail* 2008; 10: 380–387.
111. Bernardo A, Ball C, Nolasco L, et al. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. *Blood* 2004; 104: 100–106.
112. de Willige SU, Standeven KE, Philippou H, et al. The pleiotropic role of the fibrinogen gamma' chain in hemostasis. *Blood* 2009; 114: 3994–4001.
113. Grant PJ. Diabetes mellitus as a prothrombotic condition. *J Intern Med* 2007; 262: 157–172.
114. Koenig W. Fibrin(ogen) in cardiovascular disease: an update. *Thromb Haemost* 2003; 89: 601–609.
115. Lütjens A, te Velde AA, vd Veen EA, et al. Glycosylation of human fibrinogen in vivo. *Diabetologia* 1985; 28: 87–89.
116. Nair CH, Azhar A, Wilson JD, et al. Studies on fibrin network structure in human plasma. Part II--Clinical application: diabetes and antidiabetic drugs. *Thromb Res* 1991; 64: 477–485.
117. Jörneskog G, Egberg N, Fagrell B, et al. Altered properties of the fibrin gel structure in patients with IDDM. *Diabetologia* 1996; 39: 1519–1523.
118. Dunn EJ, Ariens RA, Grant PJ. The influence of type 2 diabetes on fibrin structure and function. *Diabetologia* 2005; 48: 1198–1206.
119. Fatah K, Silveira A, Tornvall P, et al. Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. *Thromb Haemost* 1996; 76: 535–540.
120. Collet JP, Allali Y, Lesty C, et al. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. *Arterioscler Thromb Vasc Biol* 2006; 26: 2567–2573.
121. Pieters M, van Zyl DG, Rheeder P, et al. Glycation of fibrinogen in uncontrolled diabetic patients and the effects of glycaemic control on fibrinogen glycation. *Thromb Res* 2007; 120: 439–446.
122. Pieters M, Covic N, van der Westhuizen FH, et al. Glycaemic control improves fibrin network characteristics in type 2 diabetes – a purified fibrinogen model. *Thromb Haemost* 2008; 99: 691–700.
123. Dunn EJ, Ariens RA. Fibrinogen and fibrin clot structure in diabetes. *Herz* 2004; 29: 470–479.
124. Iacoviello L, Vischetti M, Zito F, et al. Genes encoding fibrinogen and cardiovascular risk. *Hypertension* 2001; 38: 1199–1203.
125. Jacquemin B, Antoniadis C, Nyberg F, et al. Common genetic polymorphisms and haplotypes of fibrinogen alpha, beta, and gamma chains affect fibrinogen

- levels and the response to proinflammatory stimulation in myocardial infarction survivors: the AIRGENE study. *J Am Coll Cardiol* 2008; 52: 941–952.
126. Aso Y, Okumura K, Yoshida N, et al. Plasma interleukin-6 is associated with coagulation in poorly controlled patients with Type 2 diabetes. *Diabet Med* 2003; 20: 930–934.
 127. Müller S, Martin S, Koenig W, et al. Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-alpha or its receptors. *Diabetologia* 2002; 45: 805–812.
 128. Muszbek L, Bagoly Z, Bereczky Z, et al. The involvement of blood coagulation factor XIII in fibrinolysis and thrombosis. *Cardiovasc Hematol Agents Med Chem* 2008; 6: 190–205.
 129. Kohler HP, Stickland MH, Ossei-Gerning N, et al. Association of a common polymorphism in the factor XIII gene with myocardial infarction. *Thromb Haemost* 1998; 79: 8–13.
 130. Mansfield MW, Kohler HP, Ariens RA, et al. Circulating levels of coagulation factor XIII in subjects with type 2 diabetes and in their first-degree relatives. *Diabetes Care* 2000; 23: 703–705.
 131. Kain K, Catto AJ, Grant PJ. Associations between insulin resistance and thrombotic risk factors in high-risk South Asian subjects. *Diabet Med* 2003; 20: 651–655.
 132. Samaras K, Botelho NK, Chisholm DJ, et al. Subcutaneous and visceral adipose tissue gene expression of serum adipokines that predict type 2 diabetes. *Obesity* 2010; 18: 884–889.
 133. Distelmaier K, Adlbrecht C, Jakowitsch J, et al. Local complement activation triggers neutrophil recruitment to the site of thrombus formation in acute myocardial infarction. *Thromb Haemost* 2009; 102: 564–572.
 134. Hess K, Mathai M, Koko T, et al. Abstract 4940: Inflammatory Thrombotic Interactions in Young Type 1 Diabetes Subjects: Effects of Glycaemic Control. *Circulation* 2009; 120: S1025–S1026.
 135. Hess K, Alzahrani S, Strachan M, et al. Abstract 14996: Complement C3 and Thrombosis Risk in Diabetes: A Potential New Therapeutic Target. *Circulation* 2010; 122: A14996.
 136. Dimova EY, Kietzmann T. Metabolic, hormonal and environmental regulation of plasminogen activator inhibitor-1 (PAI-1) expression: lessons from the liver. *Thromb Haemost* 2008; 100: 992–1006.
 137. van Meijer M, Pannekoek H. Structure of plasminogen activator inhibitor 1 (PAI-1) and its function in fibrinolysis: an update. *Fibrinolysis* 1995; 9: 263–276.
 138. Stoop AA, Lupu F, Pannekoek H. Colocalization of thrombin, PAI-1, and vitronectin in the atherosclerotic vessel wall: A potential regulatory mechanism of thrombin activity by PAI-1/vitronectin complexes. *Arterioscler Thromb Vasc Biol* 2000; 20: 1143–1149.
 139. Paramo JA, Colucci M, Collen D, et al. Plasminogen activator inhibitor in the blood of patients with coronary artery disease. *Br Med J* 1985; 291: 573–574.
 140. Aznar J, Estellés A, Tormo G, et al. Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease. *Br Heart J* 1988; 59: 535–541.
 141. Juhan-Vague I, Pyke SD, Alessi MC, et al. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. *Circulation* 1996; 94: 2057–2063.
 142. Schneider DJ, Nordt TK, Sobel BE. Attenuated fibrinolysis and accelerated atherogenesis in type II diabetic patients. *Diabetes* 1993; 42: 1–7.
 143. Brazionis L, Rowley K, Jenkins A, et al. Plasminogen activator inhibitor-1 activity in type 2 diabetes: a different relationship with coronary heart disease and diabetic retinopathy. *Arterioscler Thromb Vasc Biol* 2008; 28: 786–791.
 144. Juhan-Vague I, Thompson SG, Jespersen J. Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT Angina Pectoris Study Group. *Arterioscler Thromb* 1993; 13: 1865–1873.
 145. Meltzer ME, Doggen CJ, de Groot PG, et al. Plasma levels of fibrinolytic proteins and the risk of myocardial infarction in men. *Blood* 2010; 116: 529–536.
 146. Sawdey MS, Loskutoff DJ. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. *J Clin Invest* 1991; 88: 1346–1353.
 147. Schneider DJ, Sobel BE. Synergistic augmentation of expression of plasminogen activator inhibitor type-1 induced by insulin, very-low-density lipoproteins, and fatty acids. *Coron Artery Dis* 1996; 7: 813–817.
 148. Eriksson P, Reynisdottir S, Lönnqvist F, et al. Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals. *Diabetologia* 1998; 41: 65–71.
 149. Kishore P, Li W, Tonelli J, et al. Adipocyte-derived factors potentiate nutrient-induced production of plasminogen activator inhibitor-1 by macrophages. *Sci Transl Med* 2010; 2: 20ra15.
 150. Loskutoff DJ, Samad F. The adipocyte and hemostatic balance in obesity: studies of PAI-1. *Arterioscler Thromb Vasc Biol* 1998; 18: 1–6.
 151. Fain JN, Madan AK. Insulin enhances vascular endothelial growth factor, interleukin-8, and plasminogen activator inhibitor 1 but not interleukin-6 release by human adipocytes. *Metabolism* 2005; 54: 220–226.
 152. Bastard JP, Piéroni L, Hainque B. Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance. *Diabetes Metab Res Rev* 2000; 16: 192–201.
 153. Faber DR, de Groot PG, Visseren FL. Role of adipose tissue in haemostasis, coagulation and fibrinolysis. *Obes Rev* 2009; 10: 554–563.
 154. Dobrovolsky AB, Titaeva EV. The fibrinolysis system: regulation of activity and physiologic functions of its main components. *Biochemistry* 2002; 67: 99–108.
 155. Natali A, Toschi E, Baldeweg S, et al. Clustering of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes. *Diabetes* 2006; 55: 1133–1140.
 156. Alizadeh Dehnavi R, Beishuizen ED, van de Ree MA, et al. The impact of metabolic syndrome and CRP on vascular phenotype in type 2 diabetes mellitus. *Eur J Intern Med* 2008; 19: 115–121.
 157. Meigs JB, Mittleman MA, Nathan DM, et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. *J Am Med Assoc* 2000; 283: 221–228.
 158. Takanashi K, Inukai T. Insulin resistance and changes in the blood coagulation-fibrinolysis system after a glucose clamp technique in patients with type 2 diabetes mellitus. *J Med* 2000; 31: 45–62.
 159. Eliasson MC, Jansson JH, Lindahl B, et al. High levels of tissue plasminogen activator (tPA) antigen precede the development of type 2 diabetes in a longitudinal population study. The Northern Sweden MONICA study. *Cardiovasc Diabetol* 2003; 2: 19.
 160. Tousoulis D, Antoniadou C, Bosinakou E, et al. Differences in inflammatory and thrombotic markers between unstable angina and acute myocardial infarction. *Int J Cardiol* 2007; 115: 203–207.
 161. Nordenhem A, Leander K, Hallqvist J, et al. The complex between tPA and PAI-1: risk factor for myocardial infarction as studied in the SHEEP project. *Thromb Res* 2005; 116: 223–232.
 162. Mannucci PM, Bernardinelli L, Foco L, et al. Tissue plasminogen activator antigen is strongly associated with myocardial infarction in young women. *J Thromb Haemost* 2005; 3: 280–286.
 163. Ridker PM, Vaughan DE, Stampfer MJ, et al. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. *Lancet* 1993; 341: 1165–1168.
 164. Chandler WL, Alessi MC, Aillaud MF, et al. Clearance of tissue plasminogen activator (tPA) and tPA/plasminogen activator inhibitor type 1 (PAI-1) complex: relationship to elevated tPA antigen in patients with high PAI-1 activity levels. *Circulation* 1997; 96: 761–768.
 165. Buse JB, Ginsberg HN, Bakris GL, et al. American Heart Association; American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. *Circulation* 2007; 115: 114–126.
 166. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. *Lancet* 1998; 352: 837–853.
 167. Ajan RA, Grant PJ. Cardiovascular disease prevention in patients with type 2 diabetes: The role of oral anti-diabetic agents. *Diab Vasc Dis Res* 2006; 3: 147–158.
 168. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. *Lancet* 1998; 352: 854–865.
 169. Fanghanel G, Silva U, Sanchez-Reyes L, et al. Effects of metformin on fibrinogen levels in obese patients with type 2 diabetes. *Rev Invest Clin* 1998; 50: 389–394.
 170. Grant PJ. Beneficial effects of metformin on haemostasis and vascular function in man. *Diabetes Metab* 2003; 29: 6S44–52.

171. Klaff LJ, Kernoff L, Vinik AI, et al. Sulfonylureas and platelet function. *Am J Med* 1981; 70: 627–630.
172. Ting HJ, Murray WJ, Khasawneh FT. Repurposing an old drug for a new use: glybenclamide exerts antiplatelet activity by interacting with the thromboxane A(2) receptor. *Acta Pharmacol Sin* 2010; 31: 150–159.
173. Derosa G, Franzetti I, Gadaleta G, et al. Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: comparison between glimepiride and metformin. *Diabetes Nutr Metab* 2004; 17: 143–150.
174. Khanolkar MP, Morris RH, Thomas AW, et al. Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus—an effect probably mediated by direct platelet PPAR γ activation. *Atherosclerosis* 2008; 197: 718–724.
175. Bodary PF, Vargas FB, King SA, et al. Pioglitazone protects against thrombosis in a mouse model of obesity and insulin resistance. *J Thromb Haemost* 2005; 3: 2149–2153.
176. Zirluk A, Leugers A, Lohrmann J, et al. Direct attenuation of plasminogen activator inhibitor type-1 expression in human adipose tissue by thiazolidinediones. *Thromb Haemost* 2004; 91: 674–682.
177. Marx N, Wöhrle J, Nusser T, et al. Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients. *Circulation* 2005; 112: 2792–2798.
178. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitazone Clinical Trial In macroVascular Events): a randomised controlled trial. *Lancet* 2005; 366: 1279–1289.
179. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. *N Engl J Med* 2007; 356: 2457–2471.
180. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. *Lancet* 2009; 373: 2125–2135.
181. Pignone M, Alberts MJ, Colwell JA, et al. American Diabetes Association; American Heart Association; American College of Cardiology Foundation. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. *Diabetes Care* 2010; 33: 1395–1402.
182. Scheen AJ, Legrand D. Aspirin and clopidogrel resistance in patients with diabetes mellitus. *Eur Heart J* 2006; 27: 2900.
183. Morel O, Kessler L, Ohlmann P, et al. Diabetes and the platelet: Toward new therapeutic paradigms for diabetic atherothrombosis. *Atherosclerosis* 2010; 212: 367–376.
184. Gurbel PA, Bliden KP, DiChiara J, et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. *Circulation* 2007; 115: 3156–3164.
185. Collet JP, Montalescot G. Platelet function testing and implications for clinical practice. *J Cardiovasc Pharmacol Ther* 2009; 14: 157–169.
186. Undas A, Brummel-Ziedins KE, Mann KG. Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions. *Blood* 2007; 109: 2285–2292.
187. Ajjan RA, Standeven KF, Khanbhai M, et al. Effects of aspirin on clot structure and fibrinolysis using a novel in vitro cellular system. *Arterioscler Thromb Vasc Biol* 2009; 29: 712–717.
188. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. *Lancet* 1996; 348: 1329–1339.
189. Bhatt DL, Marso SP, Hirsch AT, et al. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. *Am J Cardiol* 2002; 90: 625–628.
190. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. *Diabetes* 2005; 54: 2430–2435.
191. Angiolillo DJ, Bernardo E, Ramirez C, et al. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. *J Am Coll Cardiol* 2006; 48: 298–304.
192. Geisler T, Anders N, Paterok M, et al. Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation. *Diabetes Care* 2007; 30: 372–374.
193. Serebruany V, Pokov I, Kuliczowski W, et al. Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease. *Thromb Haemost* 2008; 100: 76–82.
194. Wiviott SD, Braunwald E, Angiolillo DJ, et al. TRITON-TIMI 38 Investigators. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. *Circulation* 2008; 118: 1626–1636.
195. James S, Angiolillo DJ, Cornel JH, et al. PLATO Study Group. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATElet inhibition and patient Outcomes (PLATO) trial. *Eur Heart J* 2010; 31: 3006–3016.
196. Lau DC, Dhillon B, Yan H, et al. Adipokines: molecular links between obesity and atherosclerosis. *Am J Physiol Heart Circ Physiol* 2005; 288: H2031–2041.
197. Kopp HP, Kopp CW, Festa A, et al. Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. *Arterioscler Thromb Vasc Biol* 2003; 23: 1042–1047.
198. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. *J Clin Invest* 2006; 116: 1793–1801.
199. Haffner SM, Greenberg AS, Weston WM, et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. *Circulation* 2002; 106: 679–684.
200. Chu NV, Kong AP, Kim DD, et al. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. *Diabetes Care* 2002; 25: 542–549.
201. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. *Arterioscler Thromb Vasc Biol* 2001; 21: 1712–1719.
202. Pierce JW, Read MA, Ding H, et al. Salicylates inhibit I kappa B-alpha phosphorylation, endothelial-leukocyte adhesion molecule expression, and neutrophil transmigration. *J Immunol* 1996; 156: 3961–3969.
203. Williamson RT. On the Treatment of Glycosuria and Diabetes Mellitus with Sodium Salicylate. *Br Med J* 1901; 1: 760–762.
204. Arkan MC, Hevener AL, Greten FR, et al. IKK-beta links inflammation to obesity-induced insulin resistance. *Nat Med* 2005; 11: 191–198.